

Syed Anwer Hussain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7924301/publications.pdf>

Version: 2024-02-01

112
papers

7,388
citations

126907

33
h-index

54911

84
g-index

114
all docs

114
docs citations

114
times ranked

11129
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
2	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 748-757.	13.7	1,142
3	Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1477-1488.	27.0	788
4	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 144-153.	2.5	217
5	BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. <i>Kidney International</i> , 2005, 68, 1834-1839.	5.2	205
6	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	1.6	202
7	Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. <i>British Journal of Cancer</i> , 2007, 96, 104-109.	6.4	184
8	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 48-55.	1.6	165
9	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015, 121, 2586-2593.	4.1	155
10	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2266-2277.	13.7	153
11	Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. <i>Annals of Oncology</i> , 2001, 12, 245-248.	1.2	133
12	Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 261-269.	0.8	115
13	The systemic treatment of advanced and metastatic bladder cancer. <i>Lancet Oncology, The</i> , 2003, 4, 489-497.	10.7	100
14	A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. <i>British Journal of Cancer</i> , 2004, 91, 844-849.	6.4	98
15	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2016, 69, 450-456.	1.9	80
16	The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 806-814.	1.6	78
17	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. <i>JAMA Oncology</i> , 2016, 2, 493.	7.1	78
18	Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. <i>European Urology</i> , 2021, 79, 621-632.	1.9	77

#	ARTICLE	IF	CITATIONS
19	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology</i> , The, 2021, 22, 246-255.	10.7	73
20	Fatty acid activated PPAR β promotes tumorigenicity of prostate cancer cells by up regulating <i>VEGF</i> via PPAR responsive elements of the promoter. <i>Oncotarget</i> , 2016, 7, 9322-9339.	1.8	68
21	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
22	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy \pm Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020, 77, 260-268.	1.9	58
23	The West Midlands Bladder Cancer Prognosis Programme: rationale and design. <i>BJU International</i> , 2010, 105, 784-788.	2.5	52
24	Successful treatment of radiation nephropathy with angiotensin II blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 190-193.	0.8	50
25	A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. <i>Oncology Letters</i> , 2012, 3, 855-859.	1.8	49
26	Systemic therapies for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1555-1568.	4.1	48
27	Live View Video Capsule Endoscopy Enables Risk Stratification of Patients with Acute Upper GI Bleeding in the Emergency Room: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2011, 56, 786-791.	2.3	43
28	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 712-723.	1.9	43
29	Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. <i>British Journal of Cancer</i> , 2003, 88, 586-592.	6.4	42
30	Bladder reconstruction: The past, present and future. <i>Oncology Letters</i> , 2015, 10, 3-10.	1.8	41
31	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 87-95.	2.3	40
32	Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. <i>Clinical Transplantation</i> , 2002, 16, 43-47.	1.6	37
33	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018, 73, 462-468.	1.9	36
34	From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. <i>European Urology Oncology</i> , 2018, 1, 486-500.	5.4	35
35	Molecular pathways in bladder cancer: Part 1. <i>BJU International</i> , 2005, 95, 485-490.	2.5	33
36	Inhibitor SBF126 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. <i>Oncotarget</i> , 2017, 8, 31041-31056.	1.8	32

#	ARTICLE	IF	CITATIONS
37	The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. <i>Oncotarget</i> , 2016, 7, 82783-82797.	1.8	30
38	Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. <i>Proteomics - Clinical Applications</i> , 2011, 5, 493-503.	1.6	29
39	Pillcam ESO [®] is more accurate than clinical scoring systems in risk stratifying emergency room patients with acute upper gastrointestinal bleeding. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 193-198.	3.2	29
40	Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. <i>European Urology</i> , 2022, 82, 273-279.	1.9	29
41	Molecular pathways in bladder cancer: Part 2. <i>BJU International</i> , 2005, 95, 491-496.	2.5	27
42	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1770-1777.	1.6	27
43	Access to Kidney Transplantation among Patients Insured by the United States Department of Veterans Affairs. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2592-2599.	6.1	24
44	A phase II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. <i>Annals of Oncology</i> , 2001, 12, 929-935.	1.2	23
45	Phosphorus-enriched hemodialysis during pregnancy: Two case reports. <i>Hemodialysis International</i> , 2005, 9, 147-152.	0.9	23
46	Molecular markers in bladder cancer. <i>Seminars in Radiation Oncology</i> , 2005, 15, 3-9.	2.2	21
47	Low vitamin D level is an independent predictor of poor outcomes in <i>Clostridium difficile</i> -associated diarrhea. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 14-19.	3.2	20
48	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , 2021, 79, 307-315.	1.9	20
49	Biology of testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1659-1673.	2.4	19
50	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19
51	Management of metastatic germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 771-784.	2.4	18
52	Cost-effectiveness of zoledronic acid and strontium ⁸⁹ as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the <i>TRAPEZE</i> trial (<i>ISRCTN</i> 12808747). <i>BJU International</i> , 2017, 119, 522-529.	2.5	18
53	Ketamine-induced Biliary Dilatation. <i>Journal of Addiction Medicine</i> , 2012, 6, 89-91.	2.6	17
54	Gene expression profiling in bladder cancer identifies potential therapeutic targets. <i>International Journal of Oncology</i> , 2017, 50, 1147-1159.	3.3	17

#	ARTICLE	IF	CITATIONS
55	Gene- and immunotherapy for hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 507-523.	3.1	16
56	Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. <i>British Journal of Cancer</i> , 2013, 109, 888-890.	6.4	16
57	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2022, 23, 650-658.	10.7	16
58	Molecularly Targeted Therapeutics for Breast Cancer. <i>BioDrugs</i> , 2007, 21, 215-224.	4.6	15
59	Multifocal Granular Cell Tumor Presenting as an Esophageal Stricture. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 107-113.	1.3	15
60	Outcome among patients with acute renal failure needing continuous renal replacement therapy: A single center study. <i>Hemodialysis International</i> , 2009, 13, 205-214.	0.9	15
61	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	1.9	15
62	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). <i>Clinical Cancer Research</i> , 2021, 27, 1882-1892.	7.0	15
63	BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 280-280.	1.6	15
64	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. <i>PLoS ONE</i> , 2020, 15, e0239338.	2.5	14
65	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 837-855.	4.1	14
66	Management of muscle invasive bladder cancer?British approaches to organ conservation. <i>Seminars in Radiation Oncology</i> , 2005, 15, 19-27.	2.2	12
67	Cisplatin- Versus Non- Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	1.9	12
68	The international normalized ratio does not reflect bleeding risk in esophageal variceal hemorrhage. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 254.	1.1	12
69	The Successful Treatment of Chronic Cholecystitis with SpyGlass Cholangioscopy-Assisted Gallbladder Drainage and Irrigation through Self- Expandable Metal Stents. <i>Gut and Liver</i> , 2012, 6, 136-138.	2.9	12
70	Organ preservation strategies in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 641-651.	2.4	11
71	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020, 3, 671-679.	5.4	11
72	Role of chemotherapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1095-1110.	2.4	10

#	ARTICLE	IF	CITATIONS
73	Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. Current Treatment Options in Oncology, 2016, 17, 15.	3.0	10
74	VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. International Journal of Oncology, 2017, 50, 768-772.	3.3	10
75	Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE).. Journal of Clinical Oncology, 2020, 38, 438-438.	1.6	10
76	Endocrine therapy and other targeted therapies for metastatic breast cancer. Expert Review of Anticancer Therapy, 2004, 4, 1179-1195.	2.4	9
77	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British Journal of Cancer, 2017, 116, 649-657.	6.4	9
78	Chemotherapy related encephalopathy in a patient with Stage IV cervical carcinoma treated with cisplatin and 5-fluorouracil: a case report. Cases Journal, 2009, 2, 8526.	0.4	7
79	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European Urology Focus, 2018, 4, 937-945.	3.1	7
80	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. European Urology Focus, 2020, 7, 554-565.	3.1	7
81	ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 2020, 21, 344.	1.6	7
82	Biology of Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2011, 25, 457-471.	2.2	6
83	Identification of Small Bowel Diverticula with Double-Balloon Enteroscopy Following Non-diagnostic Capsule Endoscopy. Digestive Diseases and Sciences, 2009, 54, 2296-2297.	2.3	5
84	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 316-320.	1.9	5
85	Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer. European Urology, 2019, 76, 604-606.	1.9	4
86	UNIQUE USAGE OF A PARTIALLY COVERED METAL STENT FOR DRAINAGE OF A PANCREATIC PSEUDOCYST VIA ENDOSONOGRAPHY-GUIDED TRANSCYSTGASTROSTOMY. Digestive Endoscopy, 2012, 24, 185-187.	2.3	3
87	Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma. Biologics: Targets and Therapy, 2013, 7, 39.	3.2	3
88	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clinical Genitourinary Cancer, 2018, 16, e161-e167.	1.9	3
89	Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. Critical Reviews in Oncology/Hematology, 2019, 140, 80-87.	4.4	3
90	Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. Gynecologic Oncology Reports, 2021, 38, 100878.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	12.8	3
92	Changing angles: Successful treatment of superior mesenteric artery syndrome with double-balloon enteroscopy-assisted direct feeding jejunostomy. Digestive Endoscopy, 2012, 24, 482-482.	2.3	2
93	Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin. European Urology, 2021, 79, 222-224.	1.9	2
94	Urological cancer patients receiving treatment during COVID-19: a single-centre perspective. British Journal of Cancer, 2021, 124, 1513-1515.	6.4	2
95	Signal Transduction Therapy: Challenges to Clinical Trial Design. Current Signal Transduction Therapy, 2007, 2, 21-30.	0.5	1
96	Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX. British Journal of Cancer, 2007, 96, 1310-1310.	6.4	1
97	Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab. Molecular and Clinical Oncology, 2021, 15, 214.	1.0	1
98	Phase I/II trial of cetuximab with 5-fluorouracil and mitomycin C concurrent with radiotherapy in patients with muscle invasive bladder cancer.. Journal of Clinical Oncology, 2017, 35, 4527-4527.	1.6	1
99	A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 200-206.	3.8	1
100	BK virus infection after renal transplantation. Current Opinion in Organ Transplantation, 2006, 11, 413-417.	1.6	0
101	Genomics and Pharmacogenomics in the Management of Breast Cancer. Current Pharmacogenomics and Personalized Medicine, 2008, 6, 45-55.	0.2	0
102	Outcomes of critically ill patients with acute kidney injury and end-stage renal disease requiring renal replacement therapy: a case-control study. Nephrology Dialysis Transplantation, 2009, 24, 2290-2290.	0.7	0
103	Therapeutics discovery: From bench to first in-human trials*. Biomedical Reports, 2018, 8, 275-282.	2.0	0
104	Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8. European Urology, 2020, 77, e156-e157.	1.9	0
105	Reply to Santhanam Sundar and Paul Symonds's Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15. European Urology, 2021, 80, e51-e52.	1.9	0
106	Active surveillance for prostate cancer: Scottish experience.. Journal of Clinical Oncology, 2012, 30, 167-167.	1.6	0
107	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2012, 30, 308-308.	1.6	0
108	A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 200-206.	3.8	0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 15, e0239338.		0
110	Title is missing!. , 2020, 15, e0239338.		0
111	Title is missing!. , 2020, 15, e0239338.		0
112	Title is missing!. , 2020, 15, e0239338.		0